Pipeline Watch: Six Approvals And Ten Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - March 16, 2026

The Autonomous Lab: Part 2
In this two-part series, In Vivo examines who is building the autonomous lab, what architectural and business model choices they are making, and what the implications are for drug discovery organizations, external R&D partnerships and the workforce that will be asked to operate these systems.
In Vivo - March 16, 2026

Deals In Depth: February 2026
Nine $1bn+ alliances were penned in February, and three exceeded $2bn. In the top alliance by deal value, Innovent Biologics entered into a potential $8.85bn collaboration with Eli Lilly to advance novel medicines in oncology and immunology.
In Vivo - March 16, 2026

‘Our Case Is About Standing Up To Patent Abuse’ – Sandoz Appeals Amgen Etanercept Antitrust Ruling
After losing US patent litigation against Amgen over Enbrel and failing to gain traction with a separate antitrust lawsuit, Sandoz isn’t giving up just yet. The firm has just filed an appeal in response to the latest district court dismissal.
Generics Bulletin - March 16, 2026

Outlook’s US Market Path Remains Murky But Builds On Europe With Ophthalmic Bevacizumab Swiss Deal
Outlook Therapeutics gave little detail about its next steps following a meeting with the US FDA, but said it was evaluating regulatory options toward approval. Meanwhile, expansion in Europe continues with a fresh Swiss commercial distribution deal.
Generics Bulletin - March 16, 2026

Opella Partners With Verb Biotics To Create ‘Next-Generation’ Microbiome Solutions
With its new parntership with Colorado's Verb Biotics, Opella says it wants to create “clinically proven gut health solutions, ready for real life.”
HBW Insight - March 16, 2026

Supply Costs Jump For India’s Medical Device Makers As Middle East Conflict Disrupts Gas Supply
India's medical device manufacturers are absorbing a cost shock on two simultaneous fronts – polymer prices up nearly 50% and gas supplies cut to 40% of contracted volumes due to the ongoing conflict in the Middle East.
Medtech Insight - March 16, 2026

‘All Patients Should Be On A Long-Acting Injectable’: Teva’s Hughes Talks Olanzapine Opportunity
Teva’s R&D chief Eric Hughes discusses the company’s long-acting injectable olanzapine program, how it could address adherence challenges in schizophrenia, and why the therapy forms a key pillar of the firm’s growing injectables franchise.
Generics Bulletin - March 16, 2026

Over The Counter: Winning In The Probiotics Space, With David Pineda Ereño
In Part 2 of HBW Insight’s Over the Counter podcast with David Pineda Ereño, we discuss how consumer health companies are navigating fragmented EU rules and leveraging e?commerce to exploit the commercial potential of postbiotics. We also briefly discuss the exciting area of postbiotics.
HBW Insight - March 16, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Roche faces giredestrant Phase III setback; founders exit BioNTech; Ipsen to withdraw Tazverik; tough times for Bayer; and another boost for UCB’s Bimzelx.
Scrip - March 16, 2026

US Tariffs Investigations Target 16 Countries For Excess Production Capacity, 60 For Forced Labor
US Trade Representative is taking two swings under Section 301(b) of the 1974 Trade Act. Customs and Border Protection has March 19 to provide US Court of International Trade with next update on its progress on providing refunds for IEEPA tariffs.
HBW Insight - March 16, 2026